clevercast
{"PLE04":{"id":"WdekGw","strictid":"PLE04","name":"PLE04","description":"","account_id":"2bK6rw","ts":0},"PLE05":{"id":"W9mpyj","strictid":"PLE05","name":"PLE05 Closing Ceremony + Concert","description":"","account_id":"2bK6rw","ts":1638855000},"SAT09":{"id":"VvyakX","strictid":"SAT09","name":"SAT09","description":"","account_id":"2bK6rw","ts":1638889200},"SPI07":{"id":"WwGDRw","strictid":"SPI07","name":"SPI07","description":"","account_id":"2bK6rw","ts":1638874920},"SCS14":{"id":"2avEmE","strictid":"SCS14","name":"SCS14","description":"","account_id":"2bK6rw","ts":1638874920},"SCS13":{"id":"A6nmKN","strictid":"SCS13","name":"SCS13","description":"","account_id":"2bK6rw","ts":1638874920},"KEY09":{"id":"Wlqkxg","strictid":"KEY09","name":"KEY09","description":"","account_id":"2bK6rw","ts":1638874920},"KEY06":{"id":"AGZbol","strictid":"KEY06","name":"KEY06","description":"","account_id":"2bK6rw","ts":1638873120},"KEY01":{"id":"AR1vr7","strictid":"KEY01","name":"KEY01","description":"","account_id":"2bK6rw","ts":1638871320},"PLE03":{"id":"VyOE09","strictid":"PLE03","name":"PLE03","description":"","account_id":"2bK6rw","ts":1638867600},"WEB05":{"id":"AKYxLw","strictid":"WEB05","name":"WEB05","description":"","account_id":"2bK6rw","ts":1638824520},"WEB04":{"id":"V316Xb","strictid":"WEB04","name":"WEB04","description":"","account_id":"2bK6rw","ts":1638817320},"KEY05":{"id":"WNKJlG","strictid":"KEY05","name":"KEY05","description":"","account_id":"2bK6rw","ts":1638811920},"SPI06":{"id":"VBXxdo","strictid":"SPI06","name":"SPI06","description":"","account_id":"2bK6rw","ts":0},"SCS12":{"id":"VYeD58","strictid":"SCS12","name":"SCS12","description":"","account_id":"2bK6rw","ts":1638810120},"SCS10":{"id":"VDrPkz","strictid":"SCS10","name":"SCS10","description":"","account_id":"2bK6rw","ts":1638810120},"KEY03":{"id":"W9mpEj","strictid":"KEY03","name":"KEY03","description":"","account_id":"2bK6rw","ts":1638810120},"SAT08":{"id":"VvyaNX","strictid":"SAT08","name":"SAT08","description":"","account_id":"2bK6rw","ts":0},"SAT07":{"id":"WwGD3w","strictid":"SAT07","name":"SAT07","description":"","account_id":"2bK6rw","ts":0},"SPI05":{"id":"VznBKn","strictid":"SPI05","name":"SPI05","description":"","account_id":"2bK6rw","ts":1638788520},"SCS11":{"id":"ApYQ5M","strictid":"SCS11","name":"SCS11","description":"","account_id":"2bK6rw","ts":1638788520},"SCS09":{"id":"2MnrZe","strictid":"SCS09","name":"SCS09","description":"","account_id":"2bK6rw","ts":1638788520},"SPI04":{"id":"Wlqkpg","strictid":"SPI04","name":"SPI04","description":"","account_id":"2bK6rw","ts":1638781320},"SCS08":{"id":"ALoQw5","strictid":"SCS08","name":"SCS08","description":"","account_id":"2bK6rw","ts":1638781320},"SCS07":{"id":"AGZbgl","strictid":"SCS07","name":"SCS07","description":"","account_id":"2bK6rw","ts":1638781320},"WEB03":{"id":"WokLe9","strictid":"WEB03","name":"WEB03","description":"","account_id":"2bK6rw","ts":1638738120},"SAT04":{"id":"Ak6yrj","strictid":"SAT04","name":"SAT04","description":"","account_id":"2bK6rw","ts":0},"SAT06":{"id":"WdekLm","strictid":"SAT06","name":"SAT06","description":"","account_id":"2bK6rw","ts":0},"KEY08":{"id":"WNKJwG","strictid":"KEY08","name":"KEY08","description":"","account_id":"2bK6rw","ts":1638716520},"KEY10":{"id":"2bzB4G","strictid":"KEY10","name":"KEY10","description":"","account_id":"2bK6rw","ts":0},"SCS04":{"id":"VPxn5l","strictid":"SCS04","name":"SCS04","description":"","account_id":"2bK6rw","ts":1638716520},"SCS03":{"id":"WdekLP","strictid":"SCS03","name":"SCS03","description":"","account_id":"2bK6rw","ts":1638716520},"SPI02":{"id":"21a6D6","strictid":"SPI02","name":"SPI02","description":"Societal impact of influenza and COVID-19","account_id":"2bK6rw","ts":1638702120},"KEY02":{"id":"VznBQJ","strictid":"KEY02","name":"KEY02","description":"","account_id":"2bK6rw","ts":1638702000},"SCS06":{"id":"ApYQJq","strictid":"SCS06","name":"SCS06","description":"Innate and adaptive immunity towards influenza, RSV disease and COVID-19","account_id":"2bK6rw","ts":1638702120},"SPI01":{"id":"AZzDlk","strictid":"SPI01","name":"SPI01","description":"Why influenza is a priority for policy makers","account_id":"2bK6rw","ts":1638694920},"SCS02":{"id":"Wj0kJZ","strictid":"SCS02","name":"SCS02","description":"Virus structure and replication in influenza virus, RSV and SARS-CoV-2; latest developments in influenza virus, SARS-CoV-2 and RSV molecular virology","account_id":"2bK6rw","ts":1638694920},"SCS01":{"id":"24amLe","strictid":"SCS01","name":"SCS01","description":"Epidemiology, surveillance and modelling of influenza, RSV disease and COVID-19, including virus evolution and strain selection","account_id":"2bK6rw","ts":1638694920},"WEB02":{"id":"Ak6yJr","strictid":"WEB02","name":"WEB02","description":"Childhood Influenza vaccination and treatment in a COVID-19 era","account_id":"2bK6rw","ts":1638651720},"OPN01":{"id":"WqYk9o","strictid":"OPN01","name":"OPN01","description":"Opening Ceremony\n","account_id":"2bK6rw","ts":1638637200},"KEY04":{"id":"27y68N","strictid":"KEY04","name":"KEY04","description":"COVID coagulopathy in comparison to influenza and pneumococci sepsis","account_id":"2bK6rw","ts":1638694920},"PER01":{"id":"2bzBJX","strictid":"PER01","name":"Permanent Livestream","description":"","account_id":"2bK6rw","ts":0},"SAT03":{"id":"VBXxaB","strictid":"SAT03","name":"SAT03","description":"","account_id":"2bK6rw","ts":1638630000},"SAT02":{"id":"VYeDlQ","strictid":"SAT02","name":"SAT02","description":"INFLUENZA AND COVID-19 Burden of Disease and Prospects for Vaccination","account_id":"2bK6rw","ts":1638622800},"SAT01":{"id":"VBXxPX","strictid":"SAT01","name":"SAT01 ","description":"Post-COVID lockdown era: what are we facing?","account_id":"2bK6rw","ts":1638615600},"WEB01":{"id":"VYeD8w","strictid":"WEB01","name":"WEB01","description":"Vaccination in a COVID-19 era","account_id":"2bK6rw","ts":1638644520},"SAT05":{"id":"ApYQNa","strictid":"SAT05","name":"SAT05","description":"Will be streamed by Roche, not from studio Antwerp, BE","account_id":"2bK6rw","ts":1638709200}}
clevercast items
{"LAN01":{"id":"WEBElL","strictid":"LAN01","name":"Lange testtrailer","description":"","account_id":"2bK6rw","chapters":[]},"TES01":{"id":"W9Jpob","strictid":"TES01","name":"Testtrailer","description":"Test trailer for scheduling Pseudo Live Events","account_id":"2bK6rw","chapters":[]}}
Sat 4 Dec
Saturday
4
December

Saturday 4 December, 12:00 - 13:45 CET

Satellite Symposium organised by Janssen: Post-COVID lockdown era: what are we facing?SAT01

Live
Time:

Saturday 4 December, 12:00 - 13:45 CET

Track:

Satellite sessions


Chairs:
Stefan Scholten, Praxis Hohenstaufenring
Carlo Federico Perno, UniCamillus International Medical University Rome

Programme:

1.     Opening remarks and introduction

Dr. med. Stefan Scholten & Professor Carlo Federico Perno

2.     COVID-19 examined: Expansion of the virus & variants

Dr. Federico Garcia, Head, Department of Microbiology, University Hospital San Cecilio

3.     The tango of interactions between respiratory viruses and the immune system: What is the result?

Professor Andrea Cossarizza, Full Professor of Pathology and Immunology, University of Modena, School of Medicine

4.     Panel discussion and live Q&A

Dr. med. Stefan Scholten, Professor Carlo Federico Perno, Dr. Federico Garcia & Professor Andrea Cossarizza

 


Programme:
  1. COVID-19 examined: Expansion of the virus & variants

    Federico Garcia, Hospital Universitario San Cecilio, Spain
  2. The tango of interactions between respiratory viruses and the immune system: What is the result?

    Andrea Cossarriza, University of Modena, Italy

Saturday 4 December, 14:00 - 15:45 CET

Satellite Symposium organised by Sanofi Pasteur: INFLUENZA AND COVID-19 Burden of Disease and Prospects for VaccinationSAT02

Live
Time:

Saturday 4 December, 14:00 - 15:45 CET

Track:

Satellite sessions


Chair:
Ursula Kunze, Medical University Vienna

Programme:
  1. Introduction and symposium opener

    Ursula Kunze, Medical University Vienna, Austria
  2. The burden of influenza and COVID-19

    Melissa K. Andrew, Dalhousie University, Canada
  3. Towards increased awareness on the evidence quality and data robustness for vaccines efficacy and effectiveness: Recent STIKO’ GRADE analysis for newer influenza vaccines in Germany

    Jörg Schelling, University Hospital of Ludwig-Maximilians - University Munich, Germany
  4. Recombinant Quadrivalent Influenza Vaccine for those 18 years of age and older

    Jaime Jesus Perez Martín, Dirección General de Salud Pública y Adicciones, Spain
  5. Lessons learnt from influenza vaccination experience to COVID-19 vaccines development

    Béhazine Combadière, Sorbonne University, France
  6. Q&A Live panel of all presenters, facilitated by the Chair

    Ursula Kunze, Medical University Vienna, Austria

Saturday 4 December, 16:00 - 17:45 CET

Satellite Symposium funded and organised by Seqirus: Influenza during COVID-19 and beyond: Challenges, Technologies and StrategiesSAT03

Live
Time:

Saturday 4 December, 16:00 - 17:45 CET

Track:

Satellite sessions


Chair:
David Salisbury, David Salisbury Consulting Limited

Programme:
  1. Perspectives from the COVID-19/influenza interface

    David Salisbury, David Salisbury Consulting Limited, United Kingdom
  2. The challenges of seasonal influenza and SARS-CoV-2 co-circulation

    Andrea Orsi, University of Genoa, Italy
  3. Differentiated vaccines for seasonal influenza prevention: Real-world evidence

    Tino Schwarz, Klinikum Würzburg Mitte, Germany
  4. Pandemic preparedness: Applying lessons from COVID-19 to influenza

    Ab Osterhaus, TiHo, Hannover, Germany
  5. Panel and audience discussion

    David Salisbury, David Salisbury Consulting Limited, United Kingdom
  6. Close

    David Salisbury, David Salisbury Consulting Limited, United Kingdom

Saturday 4 December, 18:00 - 19:00 CET

Opening CeremonyOPN01

Live
Time:

Saturday 4 December, 18:00 - 19:00 CET


Chairs:
Ab Osterhaus, TiHo, Hannover
Marco Goeijenbier, Erasmus MC
Colin Russell, Academic Medical Center, University of Amsterdam

Programme:
  1. Influenza in the time of COVID-19

    Kanta Subbarao, WHO Collaborating Centre for Reference and Research on Influenza, Australia
  2. The origins of SARS-CoV-2

    Linfa Wang, Duke-NUS Medical School, Singapore
  3. EU’s unprecedented coordinated response and further actions to mitigate the COVID-19 threat

    John Ryan, European Commission, Luxembourg

Saturday 4 December, 20:00 - 21:30 CET

Replay of Webinar: Vaccination in a COVID-19 eraWEB01

Time:

Saturday 4 December, 20:00 - 21:30 CET


This webinar was broadcasted live on Monday 20 September 2021.

Saturday 4 December, 22:00 - 23:30 CET

Replay of Webinar: Childhood Influenza vaccination and treatment in a COVID-19 eraWEB02

Time:

Saturday 4 December, 22:00 - 23:30 CET


This webinar was broadcasted live on Monday 27 September 2021.

Sun 5 Dec
Sunday
5
December

Sunday 5 December, 09:00 - 09:45 CET

Recap of of the day 4 December with Colin Russell and Ab OsterhausRECAP01

Live
Time:

Sunday 5 December, 09:00 - 09:45 CET


Highlights of yesterdays sessions and looking forward to todays programme.

Sunday 5 December, 10:00 - 10:30 CET

Keynote lecture: COVID coagulopathy in comparison to influenza and pneumococci sepsisKEY04

Time:

Sunday 5 December, 10:00 - 10:30 CET

Track:

Keynote lectures


Speaker:
Marco Goeijenbier, Erasmus MC

Sunday 5 December, 10:00 - 11:45 CET

Epidemiology, surveillance and modelling of influenza, RSV disease and COVID-19, including virus evolution and strain selectionSCS01

Time:

Sunday 5 December, 10:00 - 11:45 CET

Track:

Scientific Programme


Chairs:
Colin Russell, Academic Medical Center, University of Amsterdam
Seth Zost, Vanderbilt University Medical Center

Programme:
  1. Influenza A virus undergoes compartmentalized replication in vivo dominated by stochastic bottlenecks

    Andrew Mehle, Microbiology & Immunology, University of Wisconsin-Madison, United States of America
  2. Influenza-associated hospitalisation rates: national burden estimates for 40 countries worldwide, the Burden of Influenza and RSV Disease (BIRD) study

    John Paget, Nivel, The Netherlands
  3. Mapping the antigenic drift of N1 Neuraminidase in A(H1N1) strains from 1977-1991 to understand the childhood imprinting of anti-Neuraminidase antibodies

    Pavithra Daulagala, WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR
  4. Human and avian influenza A viruses in Cambodia during the SARS-CoV-2 pandemic, 2020-2021

    Jurre Y. Siegers, Institute Pasteur du Cambodge, Cambodia

Sunday 5 December, 10:00 - 11:45 CET

Virus structure and replication in influenza virus, RSV and SARS-CoV-2; latest developments in influenza virus, SARS-CoV-2 and RSV molecular virologySCS02

Time:

Sunday 5 December, 10:00 - 11:45 CET

Track:

Scientific Programme


Chairs:
Ed Hutchinson, University of Glasgow
Laura Martin-Sancho, Scripps Research

Programme:
  1. Coinfection with influenza A virus and respiratory syncytial virus generates a novel class of viral particles

    Joanne Haney, MRC Centre for Virus Research, University of Glasgow, United Kingdom
  2. Lab adapted vs contemporary RSVs: single amino acid changes modulate F protein mediated cell fusion

    Martin Ludlow, University of Veterinary Medicine Hannover, Germany
  3. Genomic assembly of live attenuated influenza vaccine viruses is mediated via intersegmental RNA:RNA interactions

    Sameer Ayaz, Flu-BPD, BioPharmaceuticals Development, R&D, AstraZeneca, Liverpool, United Kingdom
  4. A new structural approach to study lipid-protein interactions within a viral envelope

    Larisa Kordyukova, Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Russian Federation
  5. Adaptive evolution of PB1 from A(H1N1)pdm09 towards an enhanced compatibility between PB1 and HA

    Filipe Almeida, Antiviral Resistance Lab, Research & Development Unit, Infectious Diseases Department, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal

Sunday 5 December, 10:00 - 11:45 CET

Why influenza is a priority for policy makersSPI01

Time:

Sunday 5 December, 10:00 - 11:45 CET

Track:

Science Policy Interface


Chair:
Roman Prymula, Charles University Prague

Programme:
  1. Keynote opening: The future European Union for Health to fight influenza

    Dolors Montserrat, European Parliament, Spain
  2. Effectiveness of adjuvanted trivalent vaccine (aTIV) for influenza over 18 epidemic seasons

    Francesco Lapi, Health Search, Italian College of General Practitioners and Primary Care, Italy
  3. Public health benefits of switching into a recombinant quadrivalent vaccine in the Spanish Murcia and Valencia regions the recommended adult population (18+) for influenza seasonal vaccination.

    Georgina Drago Manchón, Sanofi Pasteur, Barcelona, Spain
  4. Open Science Practices Are Favored by Most Surveyed Influenza Researchers Despite A Lack of Perceived Peer Support

    Kelly Sutherland, The Center for Open Science, United States of America

Sunday 5 December, 12:00 - 13:45 CET

Keynote lectures on Science based management of epidemics and pandemicsKEY02

Live
Time:

Sunday 5 December, 12:00 - 13:45 CET

Tracks:

Scientific Programme, Keynote lectures


Speaker:
Ab Osterhaus, TiHo, Hannover


Programme:
  1. Household transmission studies

    Ben Cowling, The University of Hong Kong, Hong Kong S.A.R.
  2. Science based management of epidemics and pandemics

    Peter Openshaw, Imperial College London, United Kingdom

Sunday 5 December, 12:00 - 13:45 CET

Innate and adaptive immunity towards influenza, RSV disease and COVID-19SCS06

Time:

Sunday 5 December, 12:00 - 13:45 CET

Track:

Scientific Programme


Chair:
Guus Rimmelzwaan, University of Veterinary Medicine Hannover

Programme:
  1. Effects of metabolic disease on humoral immunity to SARS-CoV-2 infection

    Marcus Tong, School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Australia
  2. HLA-E-dependent antigen-specific memory NK cell responses develop against influenza nucleoprotein and are cross-reactive between antigenically distinct strains

    Stephanie Jost, Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, United States of America; Division of Innate and Comparative Immunology, Center for Human Systems Immunology, Duke University School of Medicine, United States of America
  3. DEVELOPMENT OF EXPERIMENTAL LIVE INFLUENZA VACCINE STRAINS WITH MODIFIED NP AND NS GENES

    Polina Prokopenko, Institute of Experimental Medicine, Russian Federation
  4. T-cell immune responses to live SARS-CoV-2 after natural infection and vaccination

    Irina Isakova-Sivak, Institute of Experimental Medicine, Russian Federation

Sunday 5 December, 12:00 - 13:45 CET

Societal impact of influenza and COVID-19SPI02

Time:

Sunday 5 December, 12:00 - 13:45 CET

Track:

Science Policy Interface


Chair:
Terho Heikkinen, University of Turku

Programme:
  1. The importance of vaccinating children against influenza

    Terho Heikkinen, University of Turku, Finland
  2. The Economic Burden of Influenza Among Adults Aged 18-64: A Systematic Literature Review

    Caroline de Courville, Sanofi Pasteur, France
  3. Evaluation of Psychometric Properties of a Patient-Reported Outcome Measure for the Assessment of COVID-19 Signs and Symptoms: A Cross-Sectional Observational Study

    Eric K. H. Chan, Janssen Global Services LLC, Raritan, NJ, United States of America
  4. Qualitative Interviews from a Cross-Sectional Study to Support the Content Validity of a Patient-Reported Outcome Measure of COVID-19 Signs and Symptoms in Adults

    Carla DeMuro Romano, RTI Health Solutions, Research Triangle Park, NC, United States of America

Sunday 5 December, 14:00 - 15:30 CET

Satellite symposium organised by Roche: Impact of influenza antivirals in the post–COVID-19 era and preparing for the next pandemicSAT05

Live
Time:

Sunday 5 December, 14:00 - 15:30 CET

Track:

Satellite sessions


Chair:
Tristan Clark, University of Southampton

This is a non-promotional meeting that is intended for healthcare professionals outside the United States of America


Programme:
  1. Welcome and introduction

    Tristan Clark, University of Southampton, United Kingdom
  2. Impact of COVID-19 on the clinical management of influenza patients

    Tristan Clark, University of Southampton, United Kingdom
  3. Role of antivirals in onwards transmission and prophylaxis of influenza

    Nelson Lee, University of Toronto, Canada
  4. Role of antivirals in pandemic preparedness

    Ben Cowling, The University of Hong Kong, Hong Kong S.A.R.
  5. Panel discussion: all panellists

    Tristan Clark, University of Southampton, United Kingdom
  6. Summary and closing remarks

    Tristan Clark, University of Southampton, United Kingdom
  7. Meet-the-expert session with Tristan Clark, Ben Cowling and Nelson Lee

    Tristan Clark, University of Southampton, United Kingdom

Sunday 5 December, 16:00 - 16:30 CET

Keynote lecture: Regulatory approvals in the USKEY08

Time:

Sunday 5 December, 16:00 - 16:30 CET

Track:

Keynote lectures


Speaker:
Arnold Monto, University of Michigan

Sunday 5 December, 16:00 - 17:00 CET

Poster Peek with Ab OsterhausPEEK01

Live
Time:

Sunday 5 December, 16:00 - 17:00 CET


Sunday 5 December, 16:00 - 17:45 CET

Diagnostic testing in the management of acute respiratory infections in primary and secondary careSCS03

Time:

Sunday 5 December, 16:00 - 17:45 CET

Track:

Scientific Programme


Chairs:
Michael Ison, Northwestern University
Nicole Ngai Yung Tsang, The University of Hong Kong

Programme:
  1. The impact of routine molecular point-of-care testing on hospital acquired COVID-19 infection: a pre and post implementation study

    Robert Livingstone, Division B, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
  2. IFI27 transcription as a prognostic biomarker for COVID-19

    Kirsty Short, The University of Queensland, Australia
  3. Using gargle for monitoring viral shedding in confirmed COVID-19 patients

    Nicole Ngai Yung Tsang, WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR

Sunday 5 December, 16:00 - 17:45 CET

Co-infections in influenza, RSV disease and COVID-19SCS04

Time:

Sunday 5 December, 16:00 - 17:45 CET

Track:

Scientific Programme


Chair:
Barbara Rath, Vienna Vaccine Safety Initiative

Programme:
  1. SARS-CoV-2 replication is inhibited by the presence of co-infecting respiratory viruses in differentiated human airway epithelial cells.

    Kieran Dee, Centre for Virus Research, University of Glasgow. United Kingdom
  2. Sequential delivery of LAIV and SARS-CoV-2 in the ferret model can reduce SARS-CoV-2 shedding and does not result in enhanced lung pathology.

    Katarzyna Schewe, Flu-BPD, BioPharmaceuticals Development, R&D, AstraZeneca, Liverpool, United Kingdom
  3. Legionella pneumophila affects the influenza virus-activating host cell protease-repertoire in human cells via two different mechanisms

    Marie Schwerdtner, Institute of Virology, Philipps-University Marburg, Marburg, Germany
  4. Viral co-infections in hospitalised COVID-19 patients recruited to the ISARIC WHO CCP-UK study in Scotland

    Elen Vink, Medical Research Council—University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom

Sunday 5 December, 16:30 - 17:00 CET

Keynote lecture: Next generation COVID-19 vaccinesKEY10

Time:

Sunday 5 December, 16:30 - 17:00 CET

Track:

Keynote lectures


Speaker:
Florian Krammer, Icahn School of Medicine at Mount Sinai

Sunday 5 December, 18:00 - 19:30 CET

Satellite Symposium organised by AstraZeneca: Tackling COVID-19: Exploring the prophylaxis toolkitSAT06

Live
Time:

Sunday 5 December, 18:00 - 19:30 CET

Track:

Satellite sessions


Chair:
Flor Munoz, Baylor College of Medicine

This non-promotional scientific exchange symposium has been organised and funded by AstraZeneca. 

Any information presented regarding vaccines, prophylaxis or treatment options for COVID-19 will be fair and balanced.

Veeva ID: XL-2357; Date of preparation: October 2021


Programme:
  1. Welcome & Introduction: where are we in the fight against COVID-19?

    Flor Munoz, Baylor College of Medicine, United States of America
  2. Future outlooks: strategies for COVID-19 prevention

    Hugh Montgomery, University College London / Astra Zeneca, United Kingdom
  3. Who is still at risk from COVID-19 in the post-vaccination world?

    Mona Al-Ahmad, Al-Rashed Allergy Center, Kuwait
  4. Panel discussion

    Flor Munoz, Baylor College of Medicine, United States of America

Sunday 5 December, 20:00 - 21:45 CET

Satellite Symposium organised by Pfizer: Evolving the Science of mRNA Vaccines: Helping to Protect Against COVID‐19 TodaySAT04

Live
Time:

Sunday 5 December, 20:00 - 21:45 CET

Track:

Satellite sessions


Chair:
Shanti Pather, BioNTech

Programme:
  1. Welcome and Introductions

    Shanti Pather, BioNTech, United Kingdom
  2. Evaluating the Evidence Supporting a Booster Dose of BNT162b2 COVID‐19 mRNA Vaccine

    Romina Quercia, Pfizer, United Kingdom
  3. Clinical Development of BNT162b2 COVID‐19 mRNA Vaccine in Adolescents

    David Weber, UNC School of Medicine, United States of America
  4. Faculty Panel Discussion and Q&A with Shanti Pather, Romina Quercia and David Weber

    Shanti Pather, BioNTech, United Kingdom
  5. Closing Remarks

    Shanti Pather, BioNTech, United Kingdom

Sunday 5 December, 22:00 - 23:30 CET

Replay of Webinar: COVID-19 treatment and medicationWEB03

Time:

Sunday 5 December, 22:00 - 23:30 CET


This webinar was broadcasted live on Monday 4 October 2021.

Mon 6 Dec
Monday
6
December

Monday 6 December, 09:00 - 09:45 CET

Recap of the day 5 December with Ab Osterhaus and Marco GoeijenbierRECAP02

Live
Time:

Monday 6 December, 09:00 - 09:45 CET


Highlights of yesterdays sessions and looking forward to todays programme.

Monday 6 December, 10:00 - 11:45 CET

Lessons learned from and prospects for COVID-19 vaccinationSCS07

Time:

Monday 6 December, 10:00 - 11:45 CET

Track:

Scientific Programme


Chairs:
Hanna Nohynek, Finnish Institute for Health and Welfare
Margaret Lugin, BlueWillow Biologics

Programme:
  1. Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination

    Janine Kimpel, Institute of Virology, Medical University of Innsbruck, Austria
  2. Identified Pregnancies and Associated Outcomes Across the Novavax COVID-19 Vaccine Clinical Development Program

    Hadi Beyhaghi, Novavax Inc, United States of America
  3. Nanoemulsion adjuvanted SARS-CoV-2 vaccine induces systemic and mucosal immune response following intranasal vaccination

    Margaret Lugin, BlueWillow Biologics, Ann Arbor, MI, United States of America
  4. Learnings for maximising influenza vaccine uptake during the COVID-19 vaccine roll-out; The Australian Experience in 2021.

    Paul Van Buynder, Department of Medicine, Griffith University, Southport, Queensland, Australia

Monday 6 December, 10:00 - 11:45 CET

Pandemic threats from the animal worldSCS08

Time:

Monday 6 December, 10:00 - 11:45 CET

Track:

Scientific Programme


Chair:
Ron Fouchier, Erasmus MC Rotterdam

Programme:
  1. Adaptive potential of zoonotic avian influenza virus H7N9 to ducks

    Susanne Koethe, Friedrich-Loeffler-Institut, Germany
  2. Defining the Genesis and Pathogenesis of the Avian Influenza Virus

    Lauren E Steele, School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane Australia
  3. Genetic determinants for virulence and adaptation of clade 2.3.4.4 H5N8 viruses in chickens, ducks and mammals

    Elsayed Abdelwhab, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald-Insel Riems, Germany
  4. Long term circulation of Avian Influenza Viruses Subtype H7 in wild birds in the Azov-Black Sea Region and detection of new hosts

    Denys Muzyka, National Scientific Center - Institute of Experimental and Clinical Veterinary Medicine, Ukraine

Monday 6 December, 10:00 - 11:45 CET

Benefits of vaccinating healthcare workers and other risk groupsSPI04

Time:

Monday 6 December, 10:00 - 11:45 CET

Track:

Science Policy Interface


Chair:
Antonia Ho, University of Glasgow

Programme:
  1. Introductory lecture on Benefits of vaccinating healthcare workers and other risk groups

    Antonia Ho, University of Glasgow, United Kingdom
  2. Influenza vaccination coverage rates during the COVID-19 pandemic: data from seven countries in the Northern Hemisphere

    Marco Del Riccio, Netherlands Institute for Health Services Research, Italy; Postgraduate Medical School in Public Health, University of Florence, Italy
  3. Attitude and beliefs about the seasonal influenza vaccination among Health Care Workers during Covid19 Pandemic- Kashmir, India

    Hyder Manzoor, Sheri kashmir institute of medical sciences, India
  4. Cost-Effectiveness of High-Dose Quadrivalent Influenza Vaccine (HD-QIV) Versus Adjuvanted Quadrivalent Influenza Vaccine (aQIV) in the Italian elderly population

    Filippo Rumi, Alta Scuola di Economia e Management dei Sistemi Sanitari, Università Cattolica del Sacro Cuore, Roma, Italy.

Monday 6 December, 12:00 - 13:00 CET

Poster Peek with Marco GoeijenbierPEEK02

Live
Time:

Monday 6 December, 12:00 - 13:00 CET


Monday 6 December, 12:00 - 13:45 CET

Viral and host factors in the pathogenesis of influenza, RSV diseaseSCS09

Time:

Monday 6 December, 12:00 - 13:45 CET

Track:

Scientific Programme


Chairs:
Peter Openshaw, Imperial College London
Katina Hulme, University of Queensland

Programme:
  1. Mapping influenza A virus cellular defense mechanisms reveals a strategy for evasion of autophagy

    Laura Martin-Sancho, Scripps, United States of America
  2. Precise monitoring of COVID-19 severity and treatment

    Mirella Salvatore, Department of Medicine, Weill Cornell Medicine, New York, NY, United States of America; Department of Population Health Sciences, Weill Cornell Medicine, New York, United States of America
  3. A history of obesity reduces the immune response to influenza virus in a non-canonical NLRP3-dependent manner

    Katina Hulme, School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, Australia
  4. Silencing pulmonary sensory neurons impact influenza pathogenesis

    Nathalie A.J. Verzele, Department of Anatomy and Physiology, The University of Melbourne, Australia; School of Chemistry and Molecular Biosciences, The University of Queensland, Australia
  5. Influenza NS1 protein epigenetically upregulates microRNA-146a to suppress inflammatory responses and promote viral infection

    Bobo Wing Yee Mok, State Key Laboratory for Emerging Infectious Diseases and Department of Microbiology, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong SAR

Monday 6 December, 12:00 - 13:45 CET

Experimental medicine studies of influenza, RSV disease and COVID-19SCS11

Time:

Monday 6 December, 12:00 - 13:45 CET

Track:

Scientific Programme


Chairs:
Christopher Chiu, Imperial College London
Daniel Goldhill, Imperial College

Programme:
  1. Intranasal M2SR (M2-deficient single replication) live H3N2 influenza investigational vaccine induces HAI responses against drifted influenza strains, as well as T cell responses, mucosal and serum IgA in serosusceptible adults

    Joseph Eiden, FluGen, United States of America
  2. Robust neutralizing antibody and cell mediated immune responses raised by sa-mRNA influenza vaccines co-expressing HA and NA antigens

    Yingxia Wen, Seqirus, United States of America
  3. Safety, tolerability and biological activity of repeated intranasal administration of Ampligen (Poly I:Poly C12U) as potential antiviral treatment in healthy subjects

    Johan L. van der Plas, Centre for Human Drug Research, Leiden, The Netherlands; Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands
  4. Ensovibep, a potential antiviral COVID-19 treatment, is safe and well tolerated in healthy volunteers: preliminary safety and PK results from a phase 1, multi-part, ascending, single-dose study

    Marianne Soergel, Molecular Partners AG, Schlieren, Switzerland

Monday 6 December, 12:00 - 13:45 CET

Risk assessment and risk communication in acute respiratory virus infectionsSPI05

Time:

Monday 6 December, 12:00 - 13:45 CET

Track:

Science Policy Interface


Chair:
Barbara Rath, Vienna Vaccine Safety Initiative

Programme:
  1. Understanding the variability of risk preferences for influenza vaccination among older adults (50+) during Covid19 times: a 8-country survey

    Frederic Bouder, University of Stavanger, Norway
  2. Covid-19 response in Ireland: Vaccine risk communication

    Donal O'Connor, Health Products Regulatory Authority, Ireland
  3. ImmuHubs: Improving access to vaccination in disadvantaged and difficult to reach populations

    Barbara Rath, Vienna Vaccine Safety Initiative, Germany
  4. Developing vaccine demand interventions using behavioural science and digital and social marketing practices

    Angus Thomson, UNICEF, France

Monday 6 December, 14:00 - 15:00 CET

Satellite Symposium organised by Roche: Advancing COVID-19 treatment: current and future perspectives on antiviralsSAT07

Live
Time:

Monday 6 December, 14:00 - 15:00 CET

Track:

Satellite sessions


Chair:
Frederick G. Hayden, University of Virginia

This is a non-promotional meeting that is intended for healthcare professionals outside the United States of America


Programme:
  1. Welcome and introduction

    Frederick G. Hayden, University of Virginia, United States of America
  2. Neutralising antibodies for the treatment and prevention of COVID-19

    Zain Chagla, McMaster University, Canada
  3. Data in context: the role of antivirals in the future of COVID-19 care

    Alex Soriano, Hospital Clínic of Barcelona, Spain
  4. Roundtable discussion

    Frederick G. Hayden, University of Virginia, United States of America
  5. Summary and closing remarks

    Frederick G. Hayden, University of Virginia, United States of America

Monday 6 December, 16:00 - 17:30 CET

Satellite Symposium organised by Sabin Vaccine Institute’s Influenzer Intiative: “The Influenza Vaccines R&D Roadmap: Framework for a Flu-Free Future”SAT08

Live
Time:

Monday 6 December, 16:00 - 17:30 CET

Track:

Satellite sessions


Welcome & Introduction of the IVR Initiative 

Stacey Knobler, Vice President of Vaccine Innovation, Sabin Vaccine Institute

Mike Osterholm, Director, Center for Infectious Disease Research and Policy (CIDRAP)

Video Screening: “Road to a Flu-Free Future”

Panel Discussion

Cherry Kang, Professor,The Wellcome Trust Research Laboratory, , Christian Medical College Vellore

Patrick Tippoo, Head of Science and Innovation, Biovac; Executive Director and founding member, African Vaccine Manufacturing Initiative (AVMI)

Joe Bresee, Director, Respiratory Virus Prevention Programs, Center for Vaccine Equity, Task Force for Global Health

Ethan Settembre, Vice President, Research at Seqirus

Charlie Weller, Head of Prevention, Research Programmes, Wellcome Trust

John Lim, Executive Director, Centre of Regulatory Excellence, Duke-NUS Medical School Singapore; Chairman, Consortium for Clinical Research & Innovation Singapore           

Rajeev Venkayya, President, Global Vaccine Business Unit, Takeda Pharmaceutical

Audience Question & Answer

Closing Comments & Feature Film Preview

Monday 6 December, 18:00 - 18:30 CET

Keynote lecture: Viral and host factors in the transmission of influenza and Covid-19KEY03

Time:

Monday 6 December, 18:00 - 18:30 CET

Track:

Keynote lectures


Speaker:
Wendy Barclay, Imperial College London

Monday 6 December, 18:00 - 19:45 CET

Antiviral and immune therapy for influenza, RSV disease and COVID-19SCS10

Time:

Monday 6 December, 18:00 - 19:45 CET

Track:

Scientific Programme


Chair:
Frederick G. Hayden, University of Virginia

Programme:
  1. Host- and viral-targeted antiviral development for SARS-CoV-2 and influenza virus, treating the current pandemic and preparing for the next

    Kris White, Icahn School of Medicine at Mount Sinai, United States of America
  2. Local delivery of interferon beta (SNG001) by inhalation upregulates lung antiviral biomarkers

    Phillip David Monk, Synairgen Research, Southampton General Hospital, Southampton, United Kingdom
  3. Safety, tolerability and pharmacokinetics of ensovibep in patients with mild to moderate COVID-19 - preliminary report of a phase 2a, open-label, single dose escalation study.

    J.L. van der Plas, Centre for Human Drug Research (CHDR), Leiden, The Netherlands; Department of Infectious Diseases, Leiden University Medical Center (LUMC), Leiden, The Netherlands
  4. LAT8881 and other naturally derived cytokine peptides limit respiratory virus replication and severe disease

    Michelle Tate, Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia; Department of Molecular and Translational Sciences, Monash University, Clayton, Victoria, Australia
  5. LAT8881, a novel human growth hormone fragment, is highly effective in reducing SARS-CoV-2 inflammation and lethality in a K18-hACE2 mouse model

    Matt D. Johansen, University of Technology Sydney/Centenary Institute, Australia

Monday 6 December, 18:00 - 19:45 CET

Strategies for future Influenza vaccinationSCS12

Time:

Monday 6 December, 18:00 - 19:45 CET

Track:

Scientific Programme


Chairs:
Florian Krammer, Icahn School of Medicine at Mount Sinai
Nicholas Wu, University of Illinois at Urbana-Champaign

Programme:
  1. The Safety, Immunogenicity, and Efficacy of NVX-CoV2373, a COVID-19 Vaccine, When Co-administered With Seasonal Influenza Vaccines

    Seth Toback, Novavax, United States of America
  2. Quantification of correctly-folded chimeric hemagglutinin in split inactivated influenza A and B virus vaccines

    Eduard Puente-Massaguer, Icahn School of Medicine at Mout Sinai, United States of America
  3. Pre-existing antibodies directed against a heterologous tetramerizing domain boost the immune response against artificially stabilized soluble tetrameric influenza neuraminidase

    João Paulo Portela Catani, VIB-UGent Center for Medical Biotechnology, VIB, Belgium; Department of Biochemistry and Microbiology, Ghent University, Belgium
  4. INFLUENCE OF ADJUVANTS AFTER INFLUENZA VACCINATION IN THE IMMUNODOMINANCE HIERARCHY

    Laura Sanchez-de Prada, National Influenza Center of Valladolid, Spain
  5. Novel immunogen design elicits increased protection against avian H7N9 influenza that is associated with mobilization of seasonal influenza T cell memory

    Lenny Moise, EpiVax, Inc., Providence, RI, United States of America; Center for Vaccines and Immunology, University of Georgia, Athens, GA, United States of America

Monday 6 December, 18:00 - 19:45 CET

Global health perspectives on acute respiratory virus disease and how to ensure equitable accessSPI06

Live
Time:

Monday 6 December, 18:00 - 19:45 CET

Track:

Science Policy Interface


Chair:
Ann Moen, Centers for Disease Control

Opening keynote lecture by Prof. Dr. Kwabena Frimpong-Boateng, Ghana’s Presidential Committee on Vaccine Development and Production Faculty lectures:

  • APACI: Marie-Louise McLaws
  • IFPMA: Beverley Taylor
  • African Union Commission on COVID-19: Lwazi Manzi 
  • The Rockefeller Foundation: Bruce Gellin
  • GAVI: Marta Tufet

Panel discussion Faculty lectures

  • Ready2Respond: Marie Mazur
  • PIVI: Joe Bresee
  • MOH-CDC Albania: Silvia Brino
  • MOH Armenia: Gayane Sahakyan

Panel discussion

Closing remarks

Monday 6 December, 18:30 - 19:00 CET

Keynote lecture: Antibodies against SARS-CoV-2: A Global CollaborationKEY05

Time:

Monday 6 December, 18:30 - 19:00 CET

Track:

Keynote lectures


Speaker:
Erica Ollmann Saphire, La Jolla Institute

Monday 6 December, 20:00 - 21:30 CET

Replay of Webinar: RSV disease in a COVID-19 eraWEB04

Time:

Monday 6 December, 20:00 - 21:30 CET


This webinar was broadcasted live on Monday 11 October 2021.

Monday 6 December, 22:00 - 23:30 CET

Replay of Webinar: Flu and COVID-19 booster vaccinations: where do we go?WEB05

Time:

Monday 6 December, 22:00 - 23:30 CET


This webinar was broadcasted live on Wednesday 17 November 2021.

Tue 7 Dec
Tuesday
7
December

Tuesday 7 December, 09:00 - 09:45 CET

Recap of the day 6 December with Marco Goeijenbier and Colin RussellRECAP03

Live
Time:

Tuesday 7 December, 09:00 - 09:45 CET


Highlights of yesterdays sessions and looking forward to todays programme.

Tuesday 7 December, 10:00 - 11:00 CET

Plenary session dedicated to the work of Young ScientistsPLE03

Live
Time:

Tuesday 7 December, 10:00 - 11:00 CET

Track:

Scientific Programme


Chair:
Marco Goeijenbier, Erasmus MC

Programme:
  1. The Claude Hannoun Best Body of Work Prize 2021

    Ab Osterhaus, TiHo, Hannover, Germany
  2. Immunodominance and antigenic drift: lessons from influenza and SARS-CoV-2

    Seth Zost, Vanderbilt University Medical Center, United States of America
  3. The Innovative Award 2021 supported by Seqirus

    Beverly Taylor, IFPMA, United Kingdom
  4. Public antibody responses to influenza and SARS-CoV-2

    Nicholas Wu, University of Illinois at Urbana-Champaign, United States of America

Tuesday 7 December, 11:00 - 11:30 CET

Keynote lecture: Likelihood of transmission of baloxavir-resistant influenza viruses from baloxavir-treated index patients to untreated household contacts in the BLOCKSTONE studyKEY01

Time:

Tuesday 7 December, 11:00 - 11:30 CET

Track:

Keynote lectures


Speaker:
Aeron Hurt, Roche

Tuesday 7 December, 11:00 - 12:00 CET

Poster Peek with Colin RussellPEEKO3

Live
Time:

Tuesday 7 December, 11:00 - 12:00 CET


Tuesday 7 December, 11:30 - 12:00 CET

Keynote lecture: Human challenge studies: limitations and strenghtsKEY06

Time:

Tuesday 7 December, 11:30 - 12:00 CET

Track:

Keynote lectures


Speaker:
Christopher Chiu, Imperial College London

Tuesday 7 December, 12:00 - 12:30 CET

Keynote lecture: Vaccine development and ensuring equitable acces to those most in needKEY09

Time:

Tuesday 7 December, 12:00 - 12:30 CET

Track:

Keynote lectures


Speaker:
Melanie Saville, CEPI

Tuesday 7 December, 12:00 - 13:45 CET

“Long Covid”: post and acute clinical sequelae of COVID-19SCS13

Time:

Tuesday 7 December, 12:00 - 13:45 CET

Track:

Scientific Programme


Chair:
Susanne Herold, UKGM Gießen

Programme:
  1. IL-6, IL-8 and IFN-β are elevated in individuals with long COVID

    Jane Sinclair, The University of Queensland, School of Chemistry and Molecular Biosciences, St Lucia, Australia
  2. Pulmonary function and quality of life recovery in COVID-19 pneumonia survivors

    Edita Strumiliene, Faculty of Medicine, Vilnius University, Lithuania; Vilnius University Hospital Santaros Klinikos, Lithuania
  3. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19

    Maxime Taquet, University of Oxford, United Kingdom
  4. Recovery after COVID-19 infection

    Merel Hellemons, Erasmus MC, The Netherlands

Tuesday 7 December, 12:00 - 13:45 CET

Strategies for future RSV disease vaccinationSCS14

Time:

Tuesday 7 December, 12:00 - 13:45 CET

Track:

Scientific Programme


Chair:
Rebecca Cox, University of Bergen

Programme:
  1. An Ad26.RSV.preF-based Vaccine is Effective for Prevention of RSV-mediated Lower Respiratory Tract Disease and Reduces Symptom Severity in Vaccine Recipients With RSV Infection: A Phase 2b Study in Older Adults

    Ann R Falsey, University of Rochester School of Medicine, Rochester, NY, United States of America
  2. Immunogenicity Evaluation and Regimen Selection of Prophylactic Ad26.RSV.preF Vaccine Combinations: A Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Phase 1/2a Study in Adults ≥60 Years of Age

    Arangassery Rosemary Bastian, Janssen Vaccines & Prevention B.V., Leiden, The Netherlands
  3. Induction of Broadly Cross-neutralizing Antibody Responses Against A(H3N2) and B Viruses: Results of a Phase 3 Trial of a Recombinant Quadrivalent Hemagglutinin Saponin-adjuvanted Nanoparticle Influenza Vaccine in Older Adults

    Vivek Shinde, Novavax, United States of America
  4. Safety and Tolerability of an Ad26.RSV.preF-based Vaccine in a Randomized, Double-blind, Placebo-controlled, Phase 2b Study in Adults Aged ≥65 Years

    Christy Comeaux, Janssen Vaccines & Prevention BV, Leiden, The Netherlands

Tuesday 7 December, 12:00 - 13:45 CET

Pandemic Preparedness Planning in PeacetimeSPI07

Live
Time:

Tuesday 7 December, 12:00 - 13:45 CET

Track:

Science Policy Interface


Chair:
Ab Osterhaus, TiHo, Hannover

Introductory talk: Advancing Pandemic and Seasonal Influenza Preparedness and Response

Dr. Victor Dzau, President of the Institute of Medicine, United States of America

Non-medical interventions: recommendations and lessons learned from COVID-19 for influenza

Prof. Patricia Garcia, School of Public Health, Cayetona Heredia University, Chile

Panel discussion

Tuesday 7 December, 14:00 - 15:45 CET

Satellite Symposium organised by Janssen: Shining light on the spectrum of RSV disease burden in adultsSAT09

Live
Time:

Tuesday 7 December, 14:00 - 15:45 CET

Track:

Satellite sessions


Chair:
Peter Openshaw, Imperial College London

Welcome and introduction

Peter Openshaw, Imperial College London, UK

The impact of COVID on RSV circulation

John-Sebastian Eden, Westmead Hospital, New South Wales, Australia

John-Sebastian Eden/Peter Openshaw

Adults at risk of severe RSV: The burden of RSV in adults with underlying comorbidities

Angela Branche, University of Rochester, US

Angela Branche/Peter Openshaw

RSV in older adults: An increasing problem with an aging population

Dexter Wiseman, Imperial College London, UK

Dexter Wiseman/Peter Openshaw

Interactive panel Q&A

All

Summary and meeting close

Peter Openshaw

Tuesday 7 December, 16:00 - 17:45 CET

Novel and outstanding scientific discoveries: Late BreakersPLE04

Live
Time:

Tuesday 7 December, 16:00 - 17:45 CET

Track:

Scientific Programme


Chair:
Sylvie van der Werf, Institut Pasteur

Programme:
  1. Immunogenicity and efficacy of different heterologous prime-boost vaccination regimens against swine H1N1 influenza viruses

    Anna Parys, Laboratory of Virology, Faculty of Veterinary Medicine, Ghent University, 9820 Merelbeke, Belgium
  2. Lower infectious viral load in respiratory samples of vaccinated compared to unvaccinated COVID-19 patients

    Benjamin Meyer, University of Geneva, Switzerland
  3. Ad26.RSV.preF-based vaccine regimen induced antibody Fc-effector functions and neutralization are associated with protection from respiratory syncytial virus infection

    Galit Alter, Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA United States of America
  4. Relative Vaccine Effectiveness of Cell-Based Quadrivalent Influenza Vaccine in Three Consecutive Influenza Seasons in the United States

    Constantina Boikos, Seqirus CAN Inc., Canada
  5. The regulatory role of NS gene RNA secondary structure in influenza virus life cycle

    Irina Baranovskaya, Peter the Great St.Petersburg Polytechnic University, Russian Federation; Smorodintsev Research Institute of Influenza, Russian Ministry of Health, Russian Federation

Tuesday 7 December, 18:00 - 18:30 CET

Recap of the day with Ab Osterhaus and Colin RussellRECAP04

Live
Time:

Tuesday 7 December, 18:00 - 18:30 CET


Tuesday 7 December, 18:30 - 19:00 CET

Closing CeremonyPLE05

Live
Time:

Tuesday 7 December, 18:30 - 19:00 CET


Chairs:
Ab Osterhaus, TiHo, Hannover
Colin Russell, Academic Medical Center, University of Amsterdam
Marco Goeijenbier, Erasmus MC

Tuesday 7 December, 19:00 - 20:30 CET

Farewell Concert: OtomachineCON01

Live
Time:

Tuesday 7 December, 19:00 - 20:30 CET


  FILTER